{"id":3334,"date":"2025-03-24T14:15:34","date_gmt":"2025-03-24T11:15:34","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3334"},"modified":"2025-03-24T14:26:43","modified_gmt":"2025-03-24T11:26:43","slug":"entrada-therapeutics-receives-uk-authorization-to-begin-elevate-45-201-a-phase-1-2-multiple-ascending-dose-clinical-study-of-entr-601-45-in-duchenne-muscular-dystrophy-patients-amenable-to-exon-45-sk","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/hi\/entrada-therapeutics-receives-uk-authorization-to-begin-elevate-45-201-a-phase-1-2-multiple-ascending-dose-clinical-study-of-entr-601-45-in-duchenne-muscular-dystrophy-patients-amenable-to-exon-45-sk\/","title":{"rendered":"Entrada Therapeutics \u0915\u094b ELEVATE-45-201 \u0906\u0930\u0902\u092d \u0915\u0930\u0928\u0947 \u0915\u0947 \u0932\u093f\u090f \u092f\u0942\u0928\u093e\u0907\u091f\u0947\u0921 \u0915\u093f\u0902\u0917\u0921\u092e \u092e\u0947\u0902 \u092a\u094d\u0930\u093e\u0927\u093f\u0915\u0930\u0923 \u092a\u094d\u0930\u093e\u092a\u094d\u0924 \u0939\u0941\u0906"},"content":{"rendered":"

Entrada Therapeutics \u0928\u0947 \u0918\u094b\u0937\u0923\u093e \u0915\u0940 \u0939\u0948 \u0915\u093f \u0909\u0938\u0947 \u092f\u0942\u0928\u093e\u0907\u091f\u0947\u0921 \u0915\u093f\u0902\u0917\u0921\u092e \u0915\u0940 \u092e\u0947\u0921\u093f\u0938\u093f\u0928\u094d\u0938 \u090f\u0902\u0921 \u0939\u0947\u0932\u094d\u0925\u0915\u0947\u092f\u0930 \u092a\u094d\u0930\u094b\u0921\u0915\u094d\u091f\u094d\u0938 \u0930\u0947\u0917\u0941\u0932\u0947\u091f\u0930\u0940 \u090f\u091c\u0947\u0902\u0938\u0940 (MHRA) \u0914\u0930 \u0930\u093f\u0938\u0930\u094d\u091a \u090f\u0925\u093f\u0915\u094d\u0938 \u0915\u092e\u0947\u091f\u0940 \u0938\u0947 ELEVATE-45-201 \u0936\u0941\u0930\u0942 \u0915\u0930\u0928\u0947 \u0915\u0947 \u0932\u093f\u090f \u092a\u094d\u0930\u093e\u0927\u093f\u0915\u0930\u0923 \u092a\u094d\u0930\u093e\u092a\u094d\u0924 \u0939\u0941\u0906 \u0939\u0948\u0964 ELEVATE-45-201 \u090f\u0915 \u092b\u0947\u091c 1\/2 \u092e\u0932\u094d\u091f\u0940\u092a\u0932 \u0905\u0938\u0947\u0902\u0921\u093f\u0902\u0917 \u0921\u094b\u091c (MAD) \u0915\u094d\u0932\u093f\u0928\u093f\u0915\u0932 \u0905\u0927\u094d\u092f\u092f\u0928 \u0939\u0948, \u091c\u094b Entrada \u0915\u0947 \u091c\u093e\u0902\u091a \u0914\u0937\u0927\u0940\u092f \u0909\u0924\u094d\u092a\u093e\u0926 ENTR-601-45 \u0915\u093e \u092e\u0942\u0932\u094d\u092f\u093e\u0902\u0915\u0928 \u0915\u0930\u0928\u0947 \u0915\u0947 \u0932\u093f\u090f \u0939\u0948, \u091c\u094b \u0915\u093f \u0909\u0928 \u0930\u094b\u0917\u093f\u092f\u094b\u0902 \u092e\u0947\u0902 \u0921\u094d\u092f\u0942\u091a\u0947\u0928 \u092e\u0938\u094d\u0915\u0941\u0932\u0930 \u0921\u093f\u0938\u094d\u091f\u094d\u0930\u0949\u092b\u0940 (DMD) \u0915\u0947 \u0938\u0902\u092d\u093e\u0935\u093f\u0924 \u0909\u092a\u091a\u093e\u0930 \u0915\u0947 \u0932\u093f\u090f \u0939\u0948, \u091c\u093f\u0928\u092e\u0947\u0902 DMD \u091c\u0940\u0928 \u092e\u0947\u0902 \u090f\u0915 \u092a\u0941\u0937\u094d\u091f\u093f\u0915\u0943\u0924 \u0909\u0924\u094d\u092a\u0930\u093f\u0935\u0930\u094d\u0924\u0928 \u0939\u0948, \u091c\u094b \u090f\u0915\u094d\u0938\u0949\u0928 45 \u0938\u094d\u0915\u093f\u092a\u093f\u0902\u0917 \u0915\u0947 \u0932\u093f\u090f \u0909\u0924\u094d\u0924\u0930\u0926\u093e\u092f\u0940 \u0939\u0948\u0964<\/p>\n\n\n\n

\u0914\u0930 \u0905\u0927\u093f\u0915 \u091c\u093e\u0928\u0947\u0902: \u090f\u0915\u094d\u0938\u0949\u0928 \u0938\u094d\u0915\u093f\u092a\u093f\u0902\u0917 \u0915\u094d\u092f\u093e \u0939\u0948?<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Entrada Therapeutics, announced it has received authorization from the United Kingdom\u2019s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201. ELEVATE-45-201 is a Phase 1\/2 multiple ascending dose (MAD) clinical study to evaluate Entrada\u2019s investigational medicinal product ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with […]<\/p>\n","protected":false},"author":1,"featured_media":3335,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[320,321,234,317,318,319,48,322],"class_list":["post-3334","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevate-45-201","tag-entr-601-45","tag-entrada-therapeutics","tag-exon-45","tag-exon-45-skipping","tag-exon-45-skipping-therapy","tag-uk","tag-united-kingdom"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/posts\/3334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/comments?post=3334"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/posts\/3334\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/media\/3335"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/media?parent=3334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/categories?post=3334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/hi\/wp-json\/wp\/v2\/tags?post=3334"}],"curies":[{"name":"\u0921\u092c\u094d\u0932\u094d\u092f\u0942\u092a\u0940","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}